Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOT + apatinib + sintilimab as neoadjuvant therapy for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2200055269Phase 2Completed
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Jan 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib, sintilimab, fluorouracil, folinic acid, oxaliplatin and 1 more in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Second Hospital of Lanzhou University. Primary endpoints: pathological complete response rate and disease control rate. Started Jan 2022; status: completed.
02
Drugs
Rivoceranibsintilimabfluorouracilfolinic acidoxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200055269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055269.